In transplantation, liquid biopsies that can detect donor-derived cell-free DNA (dd-cfDNA) might improve monitoring of organ rejection without invasive biopsies, and might enable effective management of anti-rejection drug therapies. Here, the authors discuss dd-cfDNA quantification methods, the clinical validity of these approaches, their limitations and economic implications.
- Michael Oellerich
- Karen Sherwood
- Philip D. Walson
